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Abstract  
The Genetic Counselling Outcome Scale (GCOS-24) is a 24-item patient reported outcome 
measure for use in evaluations of genetic counselling and testing services. The aim of this 
study was to develop a short form of GCOS-24. The study comprised three phases. Phase I: 
Cognitive interviews were used to explore interpretability of GCOS-24 items and which 
GCOS-24 items were most valued by the target population. Phase II: The Graded Response 
Model was used to analyse an existing set of GCOS-24 responses (n= 395) to examine item 
discrimination. Phase III: Item Selection. Three principles guided the approach to item 
selection (i) Items with poor discriminative properties were not selected; (ii) To avoid 
redundancy, items capturing a similar outcome were not selected together; item information 
curves and cognitive interview findings were used to establish superior items. (iii) Rasch 
analysis was then used to determine the optimal scale. In Phase I, ten cognitive interviews 
were conducted with individuals affected by or at risk for a genetic condition, recruited from 
patient support groups. Analysis of interview transcripts identified twelve GCOS-24 items 
which were highly valued by participants. In Phase II, Graded Response Model item 
characteristic curves and item information curves were produced. In Phase III, findings from 
Phases I and II were used to select ten highly-valued items that perform well. Finally, items 
were iteratively removed and permutated to establish optimal fit statistics under the Rasch 
model. A six-item questionnaire with a five-point Likert Scale was produced (The Genomics 
Outcome Scale (GOS)). Correlation between GCOS-24 and GOS scores is high (r=.838 at 
99% confidence), suggesting that GOS maintains the ability of GCOS-24 to capture 
empowerment, whilst providing a less burdensome scale for respondents. This study 
represents the first step in developing a preference-based measure which could be used in the 
evaluation of technologies and services used in genomic medicine. 
Keywords:  
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Introduction 
Genetic counselling and associated genomic testing services (hereafter shortened to ‘clinical 
genetics services’ (CGS)) have the potential to offer a number of benefits to individuals and 
families affected by conditions that may have a genetic aetiology. Recent studies have 
provided evidence that patients are seeking information and a supportive relationship, and 
that the benefits of genetic counselling include relief of uncertainty and feelings of 
vulnerability, as well as adaptation to the genetic condition in the family (Bernhardt et al., 
2000; MacLeod et al., 2002; McAllister et al., 2008; Payne et al., 2007; Skirton, 2001). 
Robust and validated measures of these benefits are needed to provide evidence to service 
commissioners about the outcomes of investing in existing CGS or future service 
developments. 
Evaluations of CGS have examined outcome variables such as knowledge, information recall, 
reproductive intentions, decisions made, anxiety or distress, patient satisfaction, perceived 
risk, perceived personal control, health behaviours, and decisional conflict (Payne et al., 
2008; Madlensky et al., 2017). There is some evidence that genetic counselling can result in 
increased knowledge, perceived personal control, positive health behaviours, and accuracy 
of perceived risk amongst patients, and decreased anxiety, worry, and decisional conflict. 
There is also evidence that patients are typically very satisfied with genetic counselling 
(Madlensky et al., 2017). 
Measures of process such as waiting times and numbers of patients seen have also been used, 
as well as the performance characteristics of genetic tests (e.g. sensitivity, specificity and 
predictive values) (Clarke et al., 1996; Payne et al., 2008). Little attention has been paid to 
exploring outcomes relevant to the population of individuals who use CGS (McAllister et al., 
2008), and there have been calls for research to identify outcomes that are most important to 
patients (Madlensky et al., 2017).  
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Moreover, many of the measures which have been used to evaluate CGS have not undergone 
rigorous psychometric validation, with many having been assessed for internal consistency 
only, and few measures assessed for important characteristics such as reliability and 
responsiveness to change (Payne et al., 2008; McAllister & Dearing 2015). 
In 2011, the Genetic Counselling Outcome Scale (GCOS-24) (Figure 1) was developed to 
provide an English language patient-reported outcome measure (PROM), specific to clinical 
genetics services (CGS) (McAllister, 2011b). GCOS-24 items are grounded in extensive 
qualitative research with CGS patients and providers, capturing an emergent theoretical 
construct labelled ‘empowerment’, comprising five sub-dimensions that summarise the 
outcomes valued by those stakeholders: cognitive, decisional and behavioural control, 
emotional regulation and hope (McAllister et al., 2008; McAllister, 2011a). ‘Empowerment’ 
was chosen as the construct name because it appeared to capture the ‘meaning’ across the 
five sub-dimensions. Despite ‘patient empowerment’ having gained considerable importance 
in healthcare policy globally, there is no universally accepted definition of the term.  Whilst 
most definitions are consistent with the approaches and principles of patient-centred care, 
patient empowerment has been conceptualised in many different ways, including as an 
underpinning ethos (e.g. that patients have rights relating to autonomy, self-determination and 
power within their healthcare relationships), as empowering interventions (e.g. shared 
decision-making) and as an indicator (e.g. a patient ‘state’ ranging from low to high levels of 
the variable ‘empowerment’) (Bravo et al, 2015).  A range of patient empowerment 
constructs have been operationalised in published measures of empowerment, including 
constructs that reflect patient states, patient experiences and capacities, patient actions and 
behaviours, patient self-determination and patient skills development (Barr et al, 2015). The 
‘empowerment’ construct operationalised in the GCOS-24 is most consistent with a patient 
‘state’. 
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GCOS-24 has been demonstrated to be valid, reliable and responsive, with no floor or ceiling 
effects observed (McAllister et al., 2011b), and has been used for service evaluation (Inglis et 
al., 2015; McAllister et al., 2016) and quality improvement (Costal-Tirado et al., 2017) in 
genetic counselling services. It has also received international attention, having been 
translated into Danish (Diness et al., 2017) and Spanish (Munoz-Caballo et al., 2018). 
<<insert Figure 1 here>> 
GCOS-24 has 24 items each with 7 response options (Figure 1). GCOS-24 generates an 
overall ‘empowerment’ score, however it is not clear what interpretation can be attached to 
differences in score and between items. Further work is needed to attach ‘preference weights’ 
to the measure, reflecting the value or priority which is placed on each item by the target 
population (Sinnott et al., 2007). This will make it clear what interpretation can be attached to 
changes in score. In its current form, however, GCOS-24 produces a substantial number of 
possible response permutations (1.92x1020). A shorter version of the scale would make it 
possible to design a study to elicit such preference weights, thereby facilitating future use of 
the shorter scale in economic evaluations of genetic and genomic testing with and without 
genetic counselling. 
Additionally, the wording of GCOS-24 items 1, 14 and 23, which refer specifically to CGS, 
means that the measure is unsuitable for use outside of CGS. Genetic testing is increasingly 
being performed outside the traditional models of service provision within CGS and is now 
moving into other specialities. This process is referred to as ‘mainstreaming genetic testing’ 
and is occurring, for example, in the context of cancer predisposition genes (Rahman, 2014), 
paediatrics (Valente et al., 2008), and neurogenetic testing (Lo et al., 2014). It is therefore 
becoming ever more important to have a valid and reliable PROM which can be used to 
evaluate genetic and genomic counselling and testing both within and outside of CGS. A 
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further added benefit of a shorter measure would be to reduce completion time, which may 
also facilitate integration into clinical care. 
In summary, a shorter version of GCOS-24 would be useful because (1) GCOS-24 is a 
thoroughly validated PROM for genetic counselling and testing services, since most other 
available CGS-specific PROMs have not been assessed for both reliability and 
responsiveness to change (2) genetic testing is increasingly being done outside the context of 
clinical genetics services, with no thoroughly validated PROM available (because GCOS-24 
has items that refer specifically to clinical genetics services) and (3) most available CGS-
specific measures have been developed for use in cancer genetics only, and are not suitable 
for general genetics services (4) there is no available PROM with attached preference weights 
that could be developed for use in economic evaluations of genetic counselling and testing 
services and (5) a shorter scale would reduce respondent burden and facilitate integration into 
clinical care. 
Over recent years, the growing emphasis on patient-centred care has accelerated the demand 
for high-quality PROM data, leading to a rise in popularity for modern psychometric methods 
such as item response theory (IRT) (Alonso et al., 2013; Nguyen, 2014). IRT methods enable 
the creation of item banks for measuring specified health status domains, which in turn 
allows for item comparison and computerised adaptive testing (CAT) tools for tailored 
assessments without loss of scale precision or content validity (Bjorner et al., 2003; Cella et 
al., 2007; Haley et al., 2004; Harniss et al., 2007). The recognised value of IRT methods is 
demonstrated by the Patient-Reported Outcome Measurement Information System (PROMIS) 
initiative in the US, which aims to catalogue validated PROMs and build accessible item 
banks for measuring key health concepts applicable to a range of conditions. 
This study aims to take the first step towards establishing a PROM which would be 
appropriate for routine use in audit and clinical evaluations of genetic services. The specific 
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aim is to develop a short form of the GCOS-24 (using both qualitative and IRT methods), 
suitable for use both within and outside the context of CGS and in research, which still 
appropriately captures the empowerment construct. 
Participant data 
For Phase I, participants were identified and recruited by Genetic Alliance UK (GAUK: 
https://www.geneticalliance.org.uk/), a national charity comprising over 180 support groups 
for genetic conditions. Phase II and Phase III used an existing dataset, comprising a set of 
responses to GCOS-24 (n=395), collected in 2010 for the original psychometric validation 
(McAllister, 2011b). Specific details (e.g. gender, ethnicity, condition type, reason for 
referral) can be found in McAllister et al. (2011b). 
Methods 
There were three phases to this study. Phase I used qualitative cognitive interviews (Ericsson 
& Simon, 1980) to explore the relevance of the existing GCOS-24 items from the perspective 
of the target population. Phase II involved analysis of an existing data set of GCOS-24 
responses (n=395) using Samejima’s Graded Response Model (GRM) (Samejima, 1969) to 
examine item discrimination. Phase III combined the results from Phases I & II to inform 
item selection, and employed the Rasch model to explore potential item combinations and 
functional problems with the seven-point Likert Scale. 
Ethics approval for the recruitment of human participants was granted by Cardiff University 
School of Medicine, 12th May 2017. Ethics approval for the secondary use of GCOS-24 
responses was granted by the National Research Ethics Service (NRES) Committee North 
West. 
Phase I: Cognitive Interviews 
Phase I used open-ended, semi structured think-aloud cognitive interviews (Ericsson & 
Simon, 1980), conducted on an individual basis. Potential participants were contacted by 
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GAUK using the following inclusion criteria: individuals who (i) are at risk of, or affected 
by, a genetic condition; (ii) are over 18 years old; (iii) have expressed an interest in 
participating in research. A Participant Information Sheet was sent to participants, and was 
provided again prior to interview. Informed consent was confirmed immediately prior to 
interview through a written, signed consent form. For interviews conducted by telephone or 
Skype, this process was done by post. 
The interview guide was adapted from the cognitive interview guide described by Irwin et al. 
(2009) and was designed to explore participants’ perceptions of the meaning and 
interpretability of GCOS-24 items, and which items were considered most important or 
relevant. Interviews were audio-recorded and then transcribed in full. Qualitative data was 
analysed using framework analysis (Ritchie & Spencer, 1994), a method which uses a pre-
determined theoretical structure to assist in the process of identifying, analysing, and 
reporting patterns (themes) within qualitative data. McAllister’s empowerment construct 
(McAllister et al., 2011a) was chosen as an appropriate framework, since GCOS-24 was 
specifically developed to capture that construct. 
Phase II: Quantitative Analysis 
An essential property for any measurement scale is the ability to discriminate between 
individuals. A scale intending to measure empowerment would be of little use if it produced 
the same results regardless of whether a person was empowered or not. One of the aims of 
reducing GCOS-24 was to retain those items which can discriminate between degrees of 
empowerment. Samejima’s GRM (Samejima, 1969) was used to analyse GCOS-24 responses 
(n=395), having separated the variables into the sub-dimensions of empowerment that each 
was designed to capture (e.g. cognitive control, behavioural control).  
GRM item characteristic curves can be used to assess the likelihood of respondents selecting 
a certain response option at various degrees of the latent trait. An item is better at 
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discriminating between individuals when the curves are peaked and dispersed across all 
levels of the latent trait. GRM item information curves show how well and precisely each 
item measures the latent trait across various levels of that trait. Certain items may display a 
skew towards lower levels of the trait, while others may skew towards higher levels. 
Comparing item information curves allows a comparison to be made between items on how 
well the latent trait is represented by the item. The R package ltm (Rizopoulos, 2006) was 
used to perform the GRM. 
Phase III: Item Selection 
Three principles guided the approach to item selection. (i) Items with poor discriminative 
properties were not selected; (ii) To avoid redundancy, items capturing a similar outcome 
were not selected together; item information curves and cognitive interview findings were 
used to establish superior items. (iii) Rasch analysis was then used to determine the optimal 
scale. 
The Rasch Rating Scale model (Andrich, 1978) was used to examine model fit and the 
reliability of potential item combinations, as well as functional problems with the 7-point 
Likert scale. The Winsteps Rasch Measurement software (Linacre, 2018) was used for Rasch 
Analysis. 
Results  
Phase I: Cognitive Interviews 
Of the 35 individuals contacted, ten (28.6%) replied and were successfully recruited to 
participate in think-aloud cognitive interviews. Participant characteristics are summarised in 
Table 1. For anonymity, participants are identified with the letter P followed by a number. 
Evidence confirming a diagnosis of a genetic condition was not sought, but all participants 
believed that their condition was genetic. 
<<insert Table 1 here>> 
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Table 2 summarises the items which were most valued by participants. For simplicity, items 
have been grouped according to which sub-dimension of McAllister’s empowerment 
framework each was designed to capture: (i) cognitive control; (ii) decisional control; (iii) 
behavioural control; (iv) emotional regulation; (v) hope (McAllister, 2011a). The qualitative 
framework analysis findings are presented below. Empowerment was sufficient to integrate 
all themes which arose from the cognitive interviews, and item numbering will be referred to 
in GCOS-24 (Figure 1). 
<<insert Table 2 here>> 
Cognitive Control 
Part of feeling empowered in relation to a genetic condition in the family is having a belief 
that you have sufficient knowledge and understanding about the condition (cognitive control) 
(McAllister et al., 2008). This could be knowledge about how the condition is inherited, what 
causes it, what the signs and symptoms are, and what the implications are for the rest of the 
family, both at present and in the future. All ten participants spoke of their desire to learn 
more about their condition, both at the time of diagnosis and as an ongoing pursuit, and of the 
benefits that this knowledge could have on their lives. On an item level, six GCOS-24 items 
had been designed to capture cognitive control: items 1, 3, 12, 14, 18, and 23 (Table 2). Of 
these, items 18 (‘I don’t know who else in my family might be at risk for this condition’) and 
12 (‘I don’t know if this condition could affect my other relatives (brothers, sisters, aunts, 
uncles, cousins)’) appeared to be valued most highly by participants. Knowing how the 
condition might affect one’s relatives was judged to be very useful information. This 
participant spoke of item 18: 
“That’s a really good question because if you, if this was day one, so you ask 
someone before their first session, they’re probably going to answer that quite high. If 
you ask them after 5 sessions, then actually the answer could be completely the 
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opposite, so I think that’s a valuable question to ask, because you can show the 
progress they’ve made and what they’ve learnt from the session. I think that’s a really 
good question. And before I had the genetic counselling I would have answered I 
don’t know, and now I can answer I do know, because I had the service and got the 
information that I needed.” (P4) 
Another participant, when considering item 12, stated: 
“I think it is an important piece of knowledge to have. If I didn’t know that 
information I would be worried, and I could see how people would get worried about 
that type of thing” (P5). 
Items 12 and 18 emerged as strong candidates for retention (Table 2). 
Decisional control 
Decisional control within the empowerment framework is not restricted only to decisions 
made about healthcare. It can include any major or minor decision which is influenced by 
having a genetic condition within the family (McAllister et al., 2008). This might involve 
decisions on marriage, whether or when to have children, or on seemingly unrelated decisions 
such as buying a car or whether to take on a mortgage. Decisional control was discussed by 
participants, however the corresponding GCOS-24 items (10, 13 and 24) were problematic. 
More specifically, items 13 (‘In relation to the condition in my family, nothing I decide will 
change the future for my children / any children I might have) and 24 (I can make decisions 
about the condition that may change my child(ren)’s future / the future of any child(ren) I 
may have) suffered because they were not seen as relevant by those participants who did not 
have children. Item 10 (‘I don’t know what could be gained from each of the options 
available to me’) was unclear to some: 
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... [Interviewer: “Are any items difficult to understand?”] “I suppose number 10: I 
don’t know what could be gained from each of the options available to me. That’s a 
little bit, what options are we talking about?” (P1) 
... [Interviewer: “What does item 10 mean to you?”] “Umm. Well the first thing that 
comes to mind after reading that question is, I don’t know what options it means. 
Umm. As far as I’m concerned I had genetic counselling, and now I’ve just got to see 
my consultant, take my medication... and that’s it. I don’t know any options that are 
available to me at all. So, it doesn’t mean a lot to me.” 
Item 24 emerged as the strongest candidate for retention, as demonstrated by the following: 
... “I like the one about decision making [item 24], ‘cause it’s the main thing; you get 
the information you want so you can make decisions. Sometimes we have to make 
decisions without all the information, so to actually have a service available to inform 
all your decision making, that’s gold you know. Wish we had it for more things. So 
yeah, if you’re only going to keep one of them, I think the decision making one is the 
best one there.” (P4) 
... “To me reading that [item 24], it’s what I do every day; I make decisions for her. If 
I feel she [the daughter] can’t do something in the normal way, then I find other 
routes so it enables her to do everything anybody else is doing. To me that is making a 
decision. So, you’re always decision making, always. You can never stop decision 
making for your child.” 
Item 24 emerged as the strongest candidate for retention (Table 2). 
Behavioural control 
Behavioural control is perhaps the most diverse dimension of empowerment, representing the 
perception of an individual that they are able to take action to improve their situation. This 
includes making effective use of the health and social care systems which are available, 
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managing the condition day to day, or communicating about genetic risks with relatives 
(McAllister et al., 2008). All participants spoke at length about the importance of outcomes 
corresponding to behavioural control. Topics included their experiences with the NHS, the 
vital importance of both medical and non-medical services following diagnosis with a genetic 
condition, and how important it is to be able to communicate with others about the condition, 
whether that be with family, work colleagues, or with a school on behalf of their child. This 
participant, for example, spoke of her experience with local support groups: 
... “The [support] groups are a massive help. I forced my sister to join. I do think that 
having a network of people going through the same thing, it doesn’t matter what your 
situation is, whether it’s, you know, cancer, depression, or anything that’s happened, 
if you’ve got a group of people going through the same thing you are, it’s ultimately 
just support and it will always help.” (P5) 
On an item level, almost all items designed to capture behavioural control were valued by 
participants. Especially popular were items 2 (‘I can explain what the condition means to 
people in my family who may need to know’) and 16 (‘I can explain what the condition 
means to people outside my family who may need to know’), with all ten expressing the 
benefits of being able to talk about the condition. This participant contextualised the outcome 
within social situations: 
... “Most people I think are naturally inquisitive. If they can see or know that an 
individual has a condition, disability, call it what you want, and if you’re able to talk 
comfortably about it, and other people around you can talk comfortably about it, and 
answer what may sometimes seem ignorant or silly questions, and you’re happy to 
take those questions, then that’s in the best interest of everybody. Whether it is 
family, friends, or work colleagues, whatever, it makes life easier for everybody.” 
(P1) 
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 A problem was observed with respect to items 5 (‘I don’t know where to go to get the 
medical help I/my family needs’) and 15 (‘I know how to get the non-medical help I / my 
family needs (e.g. educational, financial, social support)’). A common perception amongst 
even the most well-informed participants was of not being sure whether there might be more 
services out there, and as such they were reluctant to agree or disagree with these items. 
Item 7 produced contrasting interpretations over the meaning of ‘control’: 
... “I’ve got control over how people react to it, over how much people need to know, 
or how they act around my child. Obviously I can’t control how ill he’ll get. [...] I 
think that’s the bit of control I’ve got, he will be very confident. He’s going to be 
brought up very confident, and very, you know, not embarrassed about anything.” 
(P3) 
... “See I don’t like, I would take out control and I would put manage. I can’t, we have 
no control. We can only do things to lessen the impact, or try to lessen the impact. 
[...]So I don’t think you can control, ever control it. I think you can try and manage 
the condition. But control, no.” (P7) 
... “You’ve got no control over it [the condition]. Get over yourself.” (P2) 
... “I don’t know about control. [...] It’s more empowerment and advocacy of 
ownership, those are the things. Those are the terms I would be more likely to use 
over control. I don’t use control, or very rarely.” (P1) 
Aside from item 7, all items in behavioural control emerged as candidates for retention 
(Table 2). 
Emotional regulation 
Emotional regulation in the empowerment framework refers to the ability to manage the 
emotional aspects of a genetic condition, both individually and within the family (McAllister 
et al., 2011a). The diagnosis of a genetic condition can raise significant emotional challenges, 
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and it is important that these emotions are addressed by any provider of genetic counselling 
or testing services. In this study, outcomes such as guilt, anxiety, blame, helplessness, 
powerlessness, shame and sadness were brought up by participants as well as feeling “lost” 
(P6), “damaged”(P4), or “broken” (P4). 
Items 4, 11 and 21 were designed to capture emotional regulation. Of these, item 4 (‘When I 
think about the condition in my family I get upset’) emerged as the strongest candidate. Item 
21 (‘I feel guilty because I (might have) passed this condition on to my children’) was not 
seen as relevant to those without children. Item 11 (‘Having this condition in my family 
makes me feel anxious’) was highly valued by some, but overall the findings suggest that 
anxiety levels do not necessarily reduce in the long term, and instead fluctuate depending on 
the situation. This would not be a desirable item to have in an instrument which measures 
patient benefits from CGS. 
... “Having the condition in my family makes me feel anxious... I don’t think that will 
ever fully go away. I’m anxious for him [the son] when he starts a family. What if he 
gets someone pregnant and he hasn’t stopped the hydroxycarbamide? It does happen. 
I’m anxious for my future grandchildren. [...] Knowing more about it [the condition] 
has made me less anxious in one respect, but more anxious in other respects. I am 
very anxious because, even though I know a lot, I don’t feel I know everything.” (P5) 
... “[Interviewer: Does the anxiety improve over time?]” “The anxiety? ... no. Because 
the minute she has another episode you sort of take a deep breath and you hold it until 
she comes out of this episode.” 
Item 4 emerged as the strongest candidate for retention (Table 2). 
Hope 
Positivity, or a positive mind-set, was the chief manifestation of hope in this study. Item 19 
(‘I am hopeful that my children can look forward to a rewarding family life’) is only 
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applicable to those with children, and even within that demographic appeared to be of 
questionable relevance: 
... “I don’t see why you’re asking that as part of genetic counselling [laughs]. I just 
think that everybody, who would say no to that? [Continues laughing] ‘I’m going to 
have kids and I hope that they have a c**p life!’ So I don’t, if you’re trying to 
evaluate the results of these questions, I can’t see how that would help the service at 
all; because everybody always wants the best for their children. I can’t imagine 
anybody not answering positively to that.” (P4) 
Item 6 (‘I can see that good things have come from having this condition in my family’) was 
criticised for being irrelevant: 
... “I can see that good things have come from having this condition? No, no I don’t 
see that. Because we’re a close family anyway and whether this condition was there 
or not there we would still be the same close family, so that to me, that’s an irrelevant 
question. I can see good things that have come? No. (P6) 
... “Ah well we’ve got Cal [the son], ummm, I guess it makes you feel thankful in 
different ways doesn’t it, makes you appreciate little things. But... no I wouldn’t think 
that was very relevant to this sort of thing, personally.” (P3) 
Item 8 (‘I feel positive about the future’) and item 20 (‘I am able to make plans for the 
future’) emerged as the strongest candidates. Both received some criticism for being vague, 
but nevertheless were highly valued (Table 2). 
... “I mean number 8 is good, I feel positive about the future. Possibly a little bit 
vague. It doesn’t actually specify somebody might think that their horse is going to 
come in tomorrow at some race and they’re going to win a whole lot of money. They 
might be positive because of that.” (P1) 
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... “I like number 8, it’s a nice all encompassing statement. But what if somebody has 
some other issue or some other hope in their mind and they think, ‘oh yeah I’m 
positive’, it doesn’t have anything to do with this. (P1) 
... “I think it’s a good question to have in there [item 8], but it’s just a case of, I feel 
positive about the future, it’s like what aspect of the future? I feel positive about the 
future of my health, or the future of my mental health, or just feeling positive about 
the future in general. I think it’s just a bit too open ended.” (P5) 
... “[Item 20] That’s why we went really. You know, we were thinking about having a 
family. We needed the information before we put the plan in place. So yeah, that’s 
quite a valid question. (P4) 
... “[Item 20] How far in the future do they mean? Do they mean a few weeks, or a 
few years into the future? Our lives are constant planning, everything has to be risk 
assessed and planned in advance, there is very little that we can do spontaneously. 
Umm. I don’t know. It’s a difficult one because how far in advance are they asking 
you to look? Am I looking to plan 5 years, or am I looking to when my kids are 
adults? It’s difficult, I can’t really answer it.” (P7) 
Table 2 presents those items highly valued by participants for each dimension of 
empowerment. Considering the diversity of outcomes within behavioural control, and the 
high value given to them by participants, it was observed that multiple items may merit 
inclusion if they capture different aspects of the dimension. 
One noticeable trend throughout the interviews was the confusion experienced by participants 
when answering items beginning with ‘I don’t know’. Of the ten participants, seven selected 
a response option contrary to what they meant when asked about such an item. One 
individual (P4) recognised this when asked about item 18: 
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... “Erm... so I would disagree to that [item 18]. Because it’s like a negative isn’t it. 
Umm if I’ve read it correct. So it says I don’t know, but actually I’m saying I do 
know, so I would have to disagree with that statement. So that might be slightly 
confusing to someone. You may get a couple of false positives, if someone 
misunderstands the question. It is common for these, I’ve done it myself when I’ve 
had to write these kind of evaluations, as soon as you put in the word ‘I do not’ or ‘I 
don’t’, you know those kind of things, you sometimes get people who misunderstood 
the question. So I would I would say strongly disagree or disagree. Because after the 
service I did know [who else in my family might be at risk for this condition].” (P4) 
 
The consequence of this finding was an agreement within the research team that any items 
containing ‘I don’t know’ would be reworded to ‘I know’ if retained for the reduced scale. 
Phase II: Quantitative Analysis 
The Graded Response Model (GRM) 
The GCOS-24 GRM item characteristic curves (shown in Supplemental Data) demonstrate 
the likelihood of respondents selecting a certain response option at various levels of the latent 
trait. Figure 2a presents the GRM output for item 15 as an example of good discriminative 
ability. Clear peaks can be seen ordered from ‘Strongly Disagree’ at low levels of the latent 
trait to ‘Strongly Agree’ at high levels of the latent trait; a measurement scale would benefit 
from inclusion of such an item. In contrast, Figure 2b presents the GRM output for item 22, a 
poor discriminator showing that ‘Strongly Disagree’ was the primary choice across a large 
range of the underlying trait. Those items which did not discriminate well between different 
levels of latent trait were removed in Phase III. Problems included poorly defined peaks, 
meaning failure to differentiate between individuals; excessive skew, meaning a significant 
floor or ceiling effect; and excessive dominance of one response option. Such items would 
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make poor candidates for inclusion in the reduced scale. An example item information curve 
is provided in Fig 3. The plot includes items designed to capture ‘emotional regulation’, and 
shows that item 4 would be the best candidate. Complete GRM results can be found in the 
Supplemental Data, and their application to item selection is described in Phase III. 
<<insert Figure 2 here>> 
Phase III: Item Selection 
One aim of this study was to develop a measure which could be used outside the context of 
CGS, where genetic and genomic tests are done e.g. oncology, paediatrics. Items 1, 14 and 23 
were therefore not considered for selection because they specifically refer to ‘clinical genetics 
services’. The three principles of item selection will now be addressed. 
 
(i) Items with poor discriminative properties were not selected: 
Item characteristic curves were visually assessed. A flexible approach was used for data 
interpretation, since it was recognised that a number of factors may contribute to an item’s 
quantitative properties. For example, because the cognitive interview findings indicated that a 
significant proportion of respondents experience confusion when answering items beginning 
with ‘I don’t know’, such items were not immediately rejected for displaying poor 
discrimination. Additionally, items asking specifically about children were expected to show 
a prominent peak for Option 4 (‘Neither Agree nor Disagree / Not Applicable’). Following 
consideration, item 2; item 3; item 5; item 6; item 7; item 10; item 13; item 19; item 21; and 
item 22 showed an unjustifiable inability to discriminate and were therefore removed from 
further consideration. 
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(ii) To avoid redundancy, items capturing a similar outcome were not retained together; item 
information curves and cognitive interview findings were used to establish superior items: 
Cognitive control: Items 12 (‘I don’t know if this condition could affect my other relatives 
(brothers, sisters, aunts, uncles, cousins)’) and 18 (‘I don’t know who else in my family might 
be at risk for this condition’). Neither item could be differentiated based on results at this 
point. Both were highly valued by cognitive interview participants (Table 2), and GRM 
results were indivisible. 
All remaining items within decisional control, behavioural control and hope were considered 
sufficiently distinct. In emotional regulation, Item 11 was removed for having a far inferior 
item information curve to item 4 (Figure 3) and because cognitive interview results suggested 
that anxiety levels may not reduce over time, and instead fluctuate depending on the situation. 
This is not a desirable property in a scale designed to measure outcomes. 
Ten items remained in consideration at this stage (Table 3). 
<<insert Table 3 here>> 
<<insert Figure 3 here>> 
(iii) Rasch Analysis was used to determine and validate the optimal scale: 
Rasch model fit was assessed using various item combinations, with the only 
restriction/assumption being that each dimension of empowerment should be represented. A 
series of Rasch rating scale models were run starting with the selected 10 items and removing 
iteratively based on results (Table 4). Optimal performance was observed using a six-item 
scale containing items 4, 16, 17, 18, 20 and 24 (Table 4). Pearson correlation of the measure 
with this 6-item instrument with GCOS-24 was r=.838 at 99% confidence, indicating that the 
new scale retains the ability to capture the empowerment construct. The Rating scale 
characteristic curve for the short form instrument’s items (Figure 4) shows only five peaks, 
suggesting that ‘Slightly Disagree’ and ‘Slightly Agree’ could be collapsed with ‘Disagree’ 
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and ‘Agree’, respectively, without compromising scale quality. This is supported by further 
rating scale statistics (Tables 6 & 7). 
<<insert Table 4 here>> 
<<insert Figure 4 here>> 
<<insert Table 5 here>> 
<<insert Table 6 here>> 
The final 6-item scale, which we have named ‘The Genetics Outcome Scale’ (GOS) is 
presented in Figure 5. We re-named the scale in this way because the name ‘The Genetic 
Counselling Outcome Scale’ could suggest that any health care provider who discusses a 
genetic risk or a genetic test with a patient is conducting genetic counselling. One aim of 
developing the short form is to enable patient outcomes to be assessed where genetic tests are 
done outside the traditional context of clinical genetics services e.g. oncology, paediatrics. To 
eliminate the confusion over double-negatives, items 17 and 18 were re-worded to change ‘I 
don’t know’ to ‘I know’. A five-point Likert scale was adopted, and ‘Not Applicable’ was 
eliminated from the response options following indications from the results in relation to 
rating scale functioning. Such a response, if present in the middle of the scale as in GCOS-24, 
especially since in GCOS-24 it is combined with ‘neither agree nor disagree’ compromises 
the desired ordinal nature of the items and thus the quality / validity of the measurement 
construct (Smith et al., 2003). Furthermore, item 24 from GCOS-24 was re-worded to be 'I 
can make decisions about the condition that may change my future or my child(ren)'s future'. 
This was done to further eliminate the need for ‘not applicable’ responses, and because 
interview participants found items only applicable to those with children to be problematic.  
<<insert Figure 5 here>> 
Discussion 
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This study has developed a short-form (6-item) version of the Genetic Counselling Outcome 
Scale, potentially suitable for use in clinical audit and clinical evaluations of genetic 
counselling and testing services. The new scale, ‘The Genomics Outcome Scale’ or GOS, 
maintains the ability of GCOS-24 to capture the theoretical construct of empowerment 
(McAllister et al., 2011a), with the two scales showing a correlation of r=.838 at 99% 
confidence. Whilst the breadth of the latent trait captured by GCOS-24 has been maintained, 
sub-dimensional analysis will not be possible with the shorter form, though single-item 
analysis is a possibility for GOS items representing the previous sub-dimensions. With 
genetic testing increasingly being performed in contexts outside the traditional models of 
service provision (Lo et al., 2014, Rahman, 2014; Valente et al., 2008) GOS was designed to 
be applicable both within and outside of clinical genetics services. GOS provides a less 
burdensome measurement scale for respondents, and produces a significantly reduced 
number of response permutations (1.56x104) compared to GCOS-24 (1.92x1020). 
This study represents the first instance of Item Response Theory (IRT) analysis on GCOS-24, 
and findings support the call for wider use of IRT methods in PROM development 
(Embretson, 1996; Hambleton & Jones, 1993; Nguyen, 2014; Reeve, 2002). For despite 
conferring a number of benefits over the traditional approach of classical test theory (CTT), 
most notably the ability to examine measurement properties at the item-level, CTT remains 
largely unquestioned and continues to guide the construction, scoring, refinement, and 
validation of (PROMs) (Nguyen, 2014), although IRT methods are gaining traction (e.g. 
Bailey et al. (2017). Indeed the importance of IRT analysis in PROM development was 
recently emphasised by Nguyen et al. (2014), who describe how IRT can greatly improve the 
efficiency and accuracy of PROM measurement, and by Alonso et al. (2013), who discuss 
how the creation of IRT-derived item banks can benefit the outcome measurement 
community.  
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Before any instrument designed to capture the impact of specified outcomes can be used in 
research or clinical practice, COSMIN guidelines state that its measurement properties, i.e. 
reliability, responsiveness and interpretability, should be assessed and considered adequate 
(Mokkink et al., 2010). GOS shows the potential for further use, but an important limitation 
of the current study is that these properties of GOS have not yet been assessed. Further 
psychometric assessment for test-retest reliability, responsiveness and interpretability (e.g. 
establishment of the minimum clinically important difference) are needed before widespread 
use. GOS could now be used in the identification of preference-weights for each descriptive 
state represented by the items and response levels in the measure, now that the ‘Not 
Applicable’ response option has been removed. Preference weights must be elicited for all 
options to satisfy the calculations, yet assigning a value to the non-ordinal ‘Not Applicable’ 
would make the calculations unworkable. Ultimately, further testing and development of 
GOS would allow the use of this condition-specific measure as the outcome of interest in 
economic evaluations of genetic and genomic services and tests. 
One of the great strengths of GOS is that it was developed from GCOS-24: an internationally 
recognised PROM of proven validity, reliability and responsiveness which specifically 
measures outcomes valued by CGS patients. GCOS-24 content validity has previously been 
demonstrated in the context of CGS (Costal-Tirado et al., 2017; McAllister et al., 2011b), 
and clinical and research uses have been reported both in the UK and internationally (Inglis et 
al., 2014; McAllister &Dearing, 2015; Diness et al., 2017; Munoz-Cabello et al., 2017). The 
substantial qualitative research underpinning GCOS-24, coupled with the further qualitative 
research in the current study, supports the potential implementation of GOS in CGS and in 
future research, following important further psychometric assessment.  
The inclusion of both quantitative and qualitative methods in the present study design proved 
to be a valuable decision. Each provided more information on GCOS-24 items than either 
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method alone, supporting a holistic approach to item selection and strengthening the validity 
of GOS. An important limitation was the small sample size for the cognitive interviews. 
Sample homogeneity during the interview stage was a further limitation for this study, with 
all ten participants being white-British and resident in South-Wales. Cognitive interview 
findings are therefore limited to the perspective of a small number of families who live in a 
specific region and speak English. Additionally, only one of the ten interviewees self-
reported as ‘at-risk’ for a genetic condition. Seven were affected, and two were unaffected 
with an affected child. At-risk individuals are a key demographic of CGS users, and higher 
representation would have been beneficial. A further limitation was the unknown influence of 
having ‘Not Applicable’ included into Option 4 of the GCOS-24 Likert Scale. Incorporating a 
non-ordinal option into an ordinal scale disrupts the nature of the scale and would have 
affected quantitative outputs.  
Quantitative approaches should be used with caution when analysing subjective topics.  In the 
present study, rather than taking statistical findings at face value, reasonable judgement 
informed by cognitive interview findings was applied. This is emphasised by the GRM 
results in this study. Items which at first glance appeared to perform poorly could be viewed 
alongside the available interview data to reflect an issue with item wording rather than a 
problem with the underlying outcome. Items asking about children showed a prominent peak 
for the ‘Not Applicable’ response option, reflecting the reality that not all CGS users have 
children; items beginning with ‘I don’t know’ generally performed poorly, reflecting the 
reality that many people mistakenly interpret the double-negative. In short, both qualitative 
and quantitative methods offer powerful tools for PROM development. 
There is also scope to further develop GOS. The sixth item of GOS (‘I can make decisions 
about the condition that may change my child(ren)’s future / the future of any child(ren) I 
may have) will be of little relevance to those who do not have and do not plan on having 
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children; perhaps the respondent is unable to have children. Rewording the item to include a 
reference to the patient’s own future could be beneficial, e.g. ‘I can make decisions about the 
condition that may change my future, my child(ren)’s future / the future of any child(ren) I 
may have’. Furthermore, elimination of GCOS-24 item 2 (‘I can explain what the condition 
means to people in my family who may need to know’) with retention of GCOS-24 item 16 
(‘I can explain what the condition means to people outside my family who may need to 
know’) resulted in a loss of useful information. This could be addressed by merging the two 
items to create a new item: ‘I can explain what the condition means to people who may need 
to know’. Such changes, however, were beyond the scope of the present study, as the newly 
worded items and the resulting new scale would require validation. 
In conclusion, GCOS-24 has been shortened to a six-item measure with a five-point Likert 
scale (GOS). GOS has the potential to be applicable both within and outside the context of 
clinical genetics, and with only six items will be less burdensome to patients than GCOS-24. 
Correlation between the two measures (r=.838) suggests that GOS maintains the ability to 
capture the underlying construct of empowerment. This study could represent the first step in 
developing a preference-based measure for use in evaluations of genetic counselling and 
associated genomic testing services. 
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part of the study to develop and validate GCOS-24, funded by the Medical Research Council. 
Figure Titles and Legends 
 
Figure 1: The Genetic Counselling Outcome Scale (GCOS-24) (McAllister et al., 2011b). 
Figure 2: 2a (left) & 2b (right): Example GRM item characteristic curves showing items with 
good (2a) and poor (2b) discriminative properties. 
Figure 3: Example GRM item information curve (Emotional Regulation). 
Figure 4: Rating Scale characteristic curve 
Figure 5: The final scale, the Genomics Outcome Scale (GOS) 
  





























P1 Male Nystagmus Affected No No 
P2 Male Ataxia Affected No Yes 
P3 Female Tubular Sclerosis Unaffected Yes Yes 
P4 Male Glaucoma Affected No Yes 
P5 Female Thalassemia Intermedia Affected Yes Yes 
P6 Female Episodic Ataxia Unaffected Yes No 
P7 Female Ehlers Danlos Syndrome Affected Yes No 
P8 Female Dystonia & Ataxia Affected Yes No 
P9 Female Huntington’s Disease At risk Yes Yes 
P10 Male Leber’s Hereditary Optic 
Neuropathy 
Affected No No 
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Table 2: Empowerment sub-dimensions, with definitions, showing which GCOS-24 items 
were designed to capture each dimension, and which of those items were valued by cognitive 










...has sufficient information about 
the condition, including risks to 
oneself and one’s relatives, and 
any treatment, prevention and 
support available. 
1, 3, 12, 14, 18, 
23 
12 or 18 
Decisional 
Control 
...can make important life 
decisions in an informed way. 
10, 13, 24 24 
Behavioural 
Control 
...can make effective use of the 
health and social care systems 
2, 5, 7, 9, 15, 16, 
17, 22 
2 or 16; 5 or 
15; 17; 9 
Emotional 
Regulation 
...can manage their feelings about 
having a genetic condition in the 
family 
4, 11, 21 4 
Hope ...can look to the future having 
hope for a fulfilling family life, for 
oneself, one’s family, and/or one’s 
future descendants 
6, 8, 19, 20 8, 20 
 
*Highly valued items with a similar meaning are separated by ‘or’. 
 
McAllister, M., Dunn, G., Todd, C. (2011a) Empowerment: qualitative underpinning of a 
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Table 3: Items remaining in consideration following principle 2 of item selection. 
Dimension of 
Empowerment 
Item Under Consideration 
Cognitive 
Control 
(12) I don’t know if this condition could affect my other relatives (brothers, sisters, aunts, uncles, 
cousins). 
(18) I don’t know who else in my family might be at risk for this condition. 
Decisional 
Control 
(24) I can make decisions about the condition that may change my child(ren)’s future / the future of any 
child(ren) I may have. 
Behavioural 
Control 
(9) I am able to cope with having this condition in my family. 
(15) I know how to get the non-medical help I/my family needs (e.g. educational, financial, social 
support) 
(16) I can explain what the condition means to people outside my family who may need to know’ 
(17) I don’t know what I can do to change how this condition affects me/my children. 
Emotional 
Regulation 
(4) When I think about the condition in my family, I get upset. 
Hope (8) I feel positive about the future. 
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Table 4: Rasch Analysis and iterative removal of items. Bolded row corresponds to optimal 
item combination. 
 Person Item    
 Separation Reliabilit
y 







All 10 selected 
items 
1.42 0.67 9.25 0.99 1.01 (0.26) 1.05 (0.29) Item 12 (infit:1.49) 
Item 18 (1.37) 
9 items (no 18) 1.39 0.66 9.18 0.99 1.01 (0.3) 1.05 (0.34) Item 12 (1.73) 
8 items (no 18, 
9) 
1.21 0.59 9.41 0.99 1 (0.26) 1.05 (0.3) Item 12 (1.62) 
7 items (no 
8,9,18) 
1.03 0.51 9.78 0.99 1 (0.23) 1.05 (0.25) Item 12 (1.47) 
9 items (no 12) 1.5 0.69 9.96 0.99 1.01 (0.27) 1.05 (0.31) Item 18 (1.62) 
7 items (no 12, 
8, 9) 
1.15 0.57 10.56 0.99 1.01 (0.21) 1.04 (0.23) Item 18 (1.41) 
6 (no 12, 8, 9, 
15) 
1.14 0.56 11.52 0.99 1.01 (0.19) 1.04 (0.2) Item 18 (1.32) 
6 (no 12, 8, 9, 
16) 
1.06 0.53 10.45 0.99 1.02 (0.22) 1.05 (0.24) Item 18 (1.39) 
6 (no 12, 8, 9, 
17) 










Table 4. Person Separation: how efficiently a set of items can separate persons measured. Item Separation: how well a 
sample of people is able to separate each item. Person reliability: does the test discriminate the sample? Depends chiefly 
on sample ability variance, length of test, and number of categories per item. Item reliability: is the sample large enough 
to precisely locate items within the latent variable? Depends chiefly on item difficulty and person sample size. 
Infit (inlier-sensitive fit): Sensitive to response patterns to items targeted at the person. Outfit (outlier-sensitive fit): 
Sensitive to response patterns to items targeted away from the person e.g. underfit for lucky guesses or mistakes. Mean-
squares (MNSQ): the size of the randomness i.e. amount of distortion. 1.0 expected value; <1 indicates predictability and 
redundancy; >1 indicate unpredictability.  
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Table 5: Rasch results for optimal item combination (GOS). 
Item name Total Raw Score 
Observed 
Count Measure SE 
Infit Outfit 
MNSQ ZSTD MNSQ ZSTD 
GCOS4P  1261 395  0.46 0.04 1.12  1.8 1.22  2.9 
GCOS16  1948 395 -0.40 0.04  0.97  -0.4 1.02   0.4 
GCOS17P 1342 395  0.36 0.04  0.70 -5.3 0.71 -4.8 
GCOS18P 1291 395  0.42 0.04 1.32  4.5 1.32  4.3 
GCOS20  2144 395 -0.70 0.04 1.06   0.9  0.97  -0.4 
GCOS24  1751 395 -0.14 0.04  0.91 -1.5 1.02   0.4 
 Mean: 0.00  0.04 1.01  0 1.04 0.5 
 SD: 0.44  0.00  0.19  3.0  0.2 2.9 
PERSON: REAL SEPARATION.: 1.14  RELIABILITY.: 0.56   
ITEM: REAL SEPARATION: 11.52  RELIABILITY: 0.99 
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Table 6: Rasch Rating scale results. 
 Person Item   
 Separation Reliabilit
y 






1234567 à 1233345 
 
1.06 0.53 10.72 0.99 0.99 (0.18) 1.01 (0.18) 
1234567 à1223445 
 










GCOS-24 Items: Item Characteristic Curves and Item Information Curves 
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